List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4460727/publications.pdf Version: 2024-02-01

		279701	360920
106	1,773	23	35
papers	1,773 citations	h-index	g-index
115	115	115	2908
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015. Journal of Gynecologic Oncology, 2019, 30, e38.	1.0	81
2	Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clinical and Experimental Medicine, 2014, 14, 345-353.	1.9	79
3	Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028). Gynecologic Oncology, 2019, 154, 547-553.	0.6	68
4	Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea. Gynecologic Oncology, 2019, 155, 75-82.	0.6	64
5	ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. Frontiers in Oncology, 2015, 5, 167.	1.3	60
6	Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. Journal of Gynecologic Oncology, 2015, 26, 90.	1.0	57
7	PGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget, 2017, 8, 60299-60311.	0.8	54
8	Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer Research and Treatment, 2016, 48, 250-258.	1.3	52
9	Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. Biochemical Pharmacology, 2014, 92, 43-54.	2.0	50
10	Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture. Journal of Gynecologic Oncology, 2013, 24, 352.	1.0	41
11	Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin-induced apoptosis. Molecular Carcinogenesis, 2016, 55, 346-356.	1.3	40
12	Effect of Red Ginseng on Genotoxicity and Health-Related Quality of Life after Adjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer: A Randomized, Double Blind, Placebo-Controlled Trial. Nutrients, 2017, 9, 772.	1.7	38
13	Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	37
14	Major clinical research advances in gynecologic cancer in 2012. Journal of Gynecologic Oncology, 2013, 24, 66.	1.0	36
15	Major clinical research advances in gynecologic cancer in 2011. Journal of Gynecologic Oncology, 2012, 23, 53.	1.0	34
16	Cyclooxygenase-1 and -2: Molecular Targets for Cervical Neoplasia. Journal of Cancer Prevention, 2013, 18, 123-134.	0.8	31
17	Major clinical research advances in gynecologic cancer in 2013. Journal of Gynecologic Oncology, 2014, 25, 236.	1.0	30
18	Major clinical research advances in gynecologic cancer in 2014. Journal of Gynecologic Oncology, 2015, 26, 156.	1.0	29

#	Article	lF	CITATIONS
19	Major clinical research advances in gynecologic cancer in 2018. Journal of Gynecologic Oncology, 2019, 30, e18.	1.0	29
20	Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	28
21	Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Japanese Journal of Clinical Oncology, 2016, 46, 711-717.	0.6	25
22	Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells. Biomedicine and Pharmacotherapy, 2017, 96, 871-876.	2.5	25
23	Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer. Medicine (United States), 2019, 98, e15354.	0.4	25
24	Risk factors for urinary retention after vaginal hysterectomy for pelvic organ prolapse. Obstetrics and Gynecology Science, 2016, 59, 137.	0.6	24
25	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. Journal of Gynecologic Oncology, 2017, 28, e45.	1.0	24
26	Body mass index and survival in patients with epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2012, 38, 70-76.	0.6	23
27	Surgical management of recurrent ovarian cancer. Gynecologic Oncology, 2016, 142, 357-367.	0.6	23
28	Preoperative MRI criteria for trials on less radical surgery in Stage IB1 cervical cancer. Gynecologic Oncology, 2014, 134, 47-51.	0.6	21
29	The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study. Gynecologic Oncology, 2015, 137, 412-417.	0.6	20
30	Major clinical research advances in gynecologic cancer in 2015. Journal of Gynecologic Oncology, 2016, 27, e53.	1.0	20
31	Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. Journal of Gynecologic Oncology, 2018, 29, e56.	1.0	20
32	Silencing Bmi1 expression suppresses cancer stemness and enhances chemosensitivity in endometrial cancer cells. Biomedicine and Pharmacotherapy, 2018, 108, 584-589.	2.5	20
33	Major clinical research advances in gynecologic cancer in 2017. Journal of Gynecologic Oncology, 2018, 29, e31.	1.0	19
34	Major clinical research advances in gynecologic cancer in 2020. Journal of Gynecologic Oncology, 2021, 32, e53.	1.0	19
35	Circulating tumor cells in the differential diagnosis of adnexal masses. Oncotarget, 2017, 8, 77195-77206.	0.8	19
36	Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028). Cancer Research and Treatment, 2020, 52, 320-333.	1.3	19

#	Article	IF	CITATIONS
37	Major clinical research advances in gynecologic cancer in 2021. Journal of Gynecologic Oncology, 2022, 33, e43.	1.0	19
38	Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer. Journal of Cancer Prevention, 2013, 18, 227-234.	0.8	18
39	Pathologic discrepancies between colposcopy-directed biopsy and loop electrosurgical excision procedure of the uterine cervix in women with cytologic high-grade squamous intraepithelial lesions. Journal of Gynecologic Oncology, 2020, 31, e13.	1.0	18
40	Clinical evaluation of a droplet digital PCR assay for detecting <i>POLE</i> mutations and molecular classification of endometrial cancer. Journal of Gynecologic Oncology, 2022, 33, .	1.0	18
41	Major clinical research advances in gynecologic cancer in 2010. Journal of Gynecologic Oncology, 2010, 21, 209.	1.0	15
42	Pre- and intra-operative variables associated with surgical complications in elderly patients with gynecologic cancer: The clinical value of comprehensive geriatric assessment. Journal of Geriatric Oncology, 2014, 5, 315-322.	0.5	15
43	Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO). Journal of Gynecologic Oncology, 2016, 27, e36.	1.0	15
44	Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation. Nutrition and Cancer, 2018, 70, 109-115.	0.9	15
45	Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer. Anticancer Research, 2017, 37, 5087-5094.	0.5	15
46	Identifying a low-risk group for parametrial involvement in microscopic Stage IB1 cervical cancer using criteria from ongoing studies and a new MRI criterion. BMC Cancer, 2015, 15, 167.	1.1	14
47	Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. Journal of Gynecologic Oncology, 2018, 29, e60.	1.0	13
48	Role of limonin in anticancer effects of Evodia rutaecarpa on ovarian cancer cells. BMC Complementary Medicine and Therapies, 2020, 20, 94.	1.2	13
49	Pelvic Insufficiency Fractures in Cervical Cancer After Radiation Therapy: A Meta-Analysis and Review. In Vivo, 2021, 35, 1109-1115.	0.6	12
50	Matched-Case Comparisons in a Single Institution to Determine Critical Points for Inexperienced Surgeons' Successful Performances of Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Stage IA2-IIA Cervical Cancer. PLoS ONE, 2015, 10, e0131170.	1.1	11
51	Factors associated with patients' choice of physician in the Korean population: Database analyses of a tertiary hospital. PLoS ONE, 2018, 13, e0190472.	1.1	11
52	Practice Patterns of Hereditary Ovarian Cancer Management in Korea. International Journal of Gynecological Cancer, 2017, 27, 895-899.	1.2	10
53	L1 Cell Adhesion Molecule Expression Is Associated With Pelvic Lymph Node Metastasis and Advanced Stage in Diabetic Patients With Endometrial Cancer: A Matched Case Control Study. Journal of Cancer Prevention, 2014, 19, 231-239.	0.8	10
54	Major clinical research advances in gynecologic cancer in 2019. Journal of Gynecologic Oncology, 2020, 31, e48.	1.0	10

#	Article	IF	CITATIONS
55	Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea. Journal of Gynecologic Oncology, 2020, 31, e65.	1.0	10
56	A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer. BMC Cancer, 2022, 22, 28.	1,1	10
57	Impact of age on the false negative rate of human papillomavirus DNA test in patients with atypical squamous cells of undetermined significance. Obstetrics and Gynecology Science, 2015, 58, 117.	0.6	9
58	Identifying risk factors for occult lower extremity lymphedema using computed tomography in patients undergoing lymphadenectomy for gynecologic cancers. Gynecologic Oncology, 2017, 144, 153-158.	0.6	9
59	Effects of an activity tracker with feedback on physical activity in women after midline laparotomy: A randomized controlled trial. Journal of Obstetrics and Gynaecology Research, 2021, 47, 2544-2550.	0.6	9
60	Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible. Radiation Oncology, 2021, 16, 148.	1.2	9
61	Minimally invasive surgery for radical hysterectomy in women with cervical cancer: Korean Society of Gynecologic Oncology, Korean Society of Obstetrics and Gynecology, and Korean Society of Gynecologic Endoscopy and Minimally Invasive Surgery position statement. Journal of Gynecologic Oncology, 2019, 30, e104.	1.0	9
62	Risk factors for the failure of iliococcygeus suspension for uterine prolapse. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 210-213.	0.5	8
63	Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041). Cancers, 2020, 12, 3188.	1.7	8
64	Machine Learning Models to Predict Survival Outcomes According to the Surgical Approach of Primary Radical Hysterectomy in Patients with Early Cervical Cancer. Cancers, 2021, 13, 3709.	1.7	8
65	Continuous wound infiltration system for postoperative pain management in gynecologic oncology patients. Archives of Gynecology and Obstetrics, 2017, 295, 1219-1226.	0.8	7
66	Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy. Diagnostic Pathology, 2021, 16, 7.	0.9	7
67	Recommendations for gynecologic cancer care during the COVID-19 pandemic. Journal of Gynecologic Oncology, 2020, 31, e69.	1.0	7
68	Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing pelvic lymph node dissection. Obstetrics and Gynecology Science, 2017, 60, 440.	0.6	6
69	Mutually exclusive antiproliferative effect of cell lineâ€specific HOX inhibition in epithelial ovarian cancer cell lines: SKOVâ€3 vs RMUGâ€6. Journal of Cellular and Molecular Medicine, 2020, 24, 3246-3251.	1.6	6
70	Clinicopathologic and protein markers distinguishing the "polymerase epsilon exonuclease―from the "copy number low―subtype of endometrial cancer. Journal of Gynecologic Oncology, 2022, 33, .	1.0	6
71	An Occult Invasive Cervical Cancer Found After a Simple Hysterectomy: A 10-Year Experience in a Single Institution. International Journal of Gynecological Cancer, 2011, 21, 1646-1653.	1.2	5
72	Efficacy of loop electrosurgical excision procedure with cold coagulation for treating cervical intraepithelial neoplasia: A two center cohort study. Obstetrics and Gynecology Science, 2017, 60, 200.	0.6	5

#	Article	IF	CITATIONS
73	The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. Journal of Gynecologic Oncology, 2019, 30, e91.	1.0	5
74	Medroxyprogesterone Reverses Tolerable Dose Metformin-Induced Inhibition of Invasion via Matrix Metallopeptidase-9 and Transforming Growth Factor-β1 in KLE Endometrial Cancer Cells. Journal of Clinical Medicine, 2020, 9, 3585.	1.0	5
75	Effect of risk-reducing salpingo-oophorectomy on the quality of life in Korean BRCA mutation carriers. Asian Journal of Surgery, 2021, 44, 1056-1062.	0.2	5
76	Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 10255.	1.8	5
77	Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance. Anticancer Research, 2015, 35, 3909-16.	0.5	5
78	Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 415-421.	0.5	5
79	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. Journal of Obstetrics and Gynaecology Research, 2019, 46, 337-346.	0.6	4
80	Time for enhancing government-led primary prevention of cervical cancer. Journal of Gynecologic Oncology, 2021, 32, e12.	1.0	4
81	Current use of the pelvic organ prolapse quantification system in clinical practice among Korean obstetrician-gynecologists. BMC Women's Health, 2021, 21, 207.	0.8	4
82	The weekday effect on postoperative mortality in elective abdominal surgery: An observational study using propensity score methods. Surgery, 2021, 170, 186-193.	1.0	4
83	Cellular stress responses and cancer: new mechanistic insights on anticancer effect by phytochemicals. Phytochemistry Reviews, 2014, 13, 207-221.	3.1	3
84	Oligonol, a Low Molecular Weight Polyphenol, Enhances Apoptotic Cell Death in Ovarian Cancer Cells via Suppressing NF-κB Activation. Nutrition and Cancer, 2019, 71, 141-148.	0.9	3
85	Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles. BMC Cancer, 2020, 20, 1199.	1.1	3
86	The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy. International Journal of Gynecological Cancer, 2020, 30, 975-980.	1.2	3
87	Calcitriol Combined With Platinum-based Chemotherapy Suppresses Growth and Expression of Vascular Endothelial Growth Factor of SKOV-3 Ovarian Cancer Cells. Anticancer Research, 2021, 41, 2945-2952.	0.5	3
88	Cervical Cancer in Women with Normal Papanicolaou Tests: A Korean Nationwide Cohort Study. Cancer Research and Treatment, 2021, 53, 813-818.	1.3	3
89	Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology. Anticancer Research, 2015, 35, 4197-202.	0.5	3
90	Do fertile women have an inferior treatment for highâ€grade precancerous lesions?. Journal of Obstetrics and Gynaecology Research, 2018, 44, 772-777.	0.6	2

#	Article	IF	CITATIONS
91	Pilot study of radiofrequency thermal therapy performed twice on the entire vaginal wall for vaginal laxity. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 159-163.	0.5	2
92	The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer. Journal of Clinical Medicine, 2020, 9, 2960.	1.0	2
93	Successful pregnancy following transmyometrial embryo transfer after robot-assisted radical trachelectomy. Clinical and Experimental Reproductive Medicine, 2021, 48, 184-187.	0.5	2
94	Current techniques used to perform surgery for anterior and posterior vaginal wall prolapse in South Korea. Obstetrics and Gynecology Science, 2022, 65, 273-278.	0.6	2
95	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Medical Ethics, 2016, 17, 63.	1.0	1
96	Preoperative POPQ versus Simulated Apical Support as a Guideline for Anterior or Posterior Repair at the Time of Transvaginal Apical Suspension (PREPARE trial): study protocol for a randomised controlled trial. BMJ Open, 2020, 10, e034170.	0.8	1
97	Non-absorbable versus absorbable sutures for anterior colporrhaphy: study protocol for a randomised controlled trial in South Korea. BMJ Open, 2020, 10, e034218.	0.8	1
98	Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial. Experimental and Therapeutic Medicine, 2021, 22, 787.	0.8	1
99	The association between diarrhea and serum cytokines in patients with gynecologic cancer treated with surgery and pelvic chemoradiotherapy. Clinical and Translational Radiation Oncology, 2021, 29, 60-64.	0.9	1
100	Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy. Obstetrics and Gynecology Science, 2019, 62, 285.	0.6	1
101	Use of a ring retractor to facilitate specimen removal in laparoscopic surgery. Obstetrics and Gynecology Science, 2020, 63, 548-549.	0.6	1
102	Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	1
103	Laparoscopic surgery is a current tide of widely accepted standard procedure for endometrial cancer. Journal of Gynecologic Oncology, 2010, 21, 67.	1.0	0
104	Clinical features that affect the number of pelvic lymph nodes harvested in patients with cervical cancer stage IB1 to IIA2. Obstetrics and Gynecology Science, 2021, 64, 73-79.	0.6	0
105	Abstract 617: Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer. , 2021, , .		0
106	The voiding VAS score is a simple and useful method for predicting POUR after laparoscopy for benign gynaecologic diseases: a pilot study. Journal of Obstetrics and Gynaecology, 0, , 1-6.	0.4	0